OUR SCIENCE
What we create
MultiTEP: A Breakthrough in Neurodegenerative Disease Research
We developed MultiTEP, an innovative vaccine platform, specifically for neurodegenerative disorders like Alzheimer’s disease (AD) and Parkinson’s disease (PD). MultiTEP is a universal, highly immunogenic recombinant protein vaccine designed to generate high concentrations of antibodies against pathological molecules.
The MultiTEP platform combines diverse T-helper (Th) epitopes with PADRE, a universal synthetic peptide, to activate Th cells. This ensures binding to various human MHC polymorphisms and activates both naive and memory Th cells. These linked epitopes, attached to disease-related protein targets, are injected with a highly immunogenic adjuvant to spur antibody production.
Our preclinical MultiTEP studies have generated outstanding results. The platform evoked high immunogenicity and generated a robust antibody response against disease-related proteins in mice, rabbits, and non-human primates. This represents a significant step forward in the pursuit of effective neurodegenerative disease treatments.
The MultiTEP platform combines diverse T-helper (Th) epitopes with PADRE, a universal synthetic peptide, to activate Th cells. This ensures binding to various human MHC polymorphisms and activates both naive and memory Th cells. These linked epitopes, attached to disease-related protein targets, are injected with a highly immunogenic adjuvant to spur antibody production.
Our preclinical MultiTEP studies have generated outstanding results. The platform evoked high immunogenicity and generated a robust antibody response against disease-related proteins in mice, rabbits, and non-human primates. This represents a significant step forward in the pursuit of effective neurodegenerative disease treatments.
B-cell oriented epitope
T-cell oriented epitope
Universal MultiTEP platform
We incorporate three copies of each target epitope to enhance antibody production
MultiTEP evokes a robust Th-cell signal that significantly increases antibody production
We combine MultiTEP with a novel adjuvant to further boost antibody generation
Adjuvant
We attach B-cell epitopes from disease-related proteins to the MultiTEP platform to generate a high-titer, recombinant protein vaccine
01.
Target not only naïve, but also pre-existing memory Th cells specific to pathogens that most adults would have either been exposed to or vaccinated against, and taking advantage of the high levels of memory Th cells overcome immunosenescence in the elderly
Avoid the generation of harmful autoreactive T cells (e.g., specific to self Aβ, tau, α-syn, etc.)
Activate a broad repertoire of Th cells providing broad coverage of the targeted population with high MHC class II gene polymorphism
02.
03.
04.
Alzheimer’s Stages
Nuravax Vaccines
40 — 55 years old
55 — 60 years old
65 — 75 years old
Overcome self-tolerance by activating T helper (Th) cells specific to mixed foreign epitopes
Target naïve and memory Th cells specific to common pathogens to overcome immunosenescence in elderly patients
Avoid the generation of harmful autoreactive T cells that contribute to autoimmune disease
Activate a broad repertoire of Th cells and MHC class II gene polymorphisms
Preclinical Alzheimer's
Acquires subtle changes in the brain, biomarkers in the cerebrospinal fluid, and blood. No memory problems or other symptoms
Acquires subtle changes in the brain, biomarkers in the cerebrospinal fluid, and blood. No memory problems or other symptoms
Mild cognitive impairment
Exhibits changes in memory and other cognitive functions, like problem solving and judgment, that do not affect daily functioning
Exhibits changes in memory and other cognitive functions, like problem solving and judgment, that do not affect daily functioning
Moderate dementia
Forgets a major relevant aspect of their current life, a familiar address or telephone number, or names of close family members
Forgets a major relevant aspect of their current life, a familiar address or telephone number, or names of close family members
Based on observations in aged non-human primates, we believe MultiTEP may be especially beneficial in elderly patients
Severe dementia
Occasionally forgets the name of the spouse or caregiver upon whom they are entirely dependent
Occasionally forgets the name of the spouse or caregiver upon whom they are entirely dependent
75 — 85 years old
Our goal is to generate disease-related protein antibodies that cross the blood-brain barrier at high concentrations. This will prevent the formation of harmful brain plaques and oligomers, thereby preserving normal brain function.
Our strategy is to deliver an effective concentration of antibodies across the blood-brain barrier over the long term to halt or delay the onset of neurodegenerative disease.